Amgen Inc (AMGN)

163.36
0.64 0.39
NASDAQ : Health Care
Prev Close 162.72
Open 162.39
Day Low/High 161.53 / 163.48
52 Wk Low/High 130.09 / 181.81
Volume 2.94M
Avg Volume 3.80M
Exchange NASDAQ
Shares Outstanding 735.89M
Market Cap 121.13B
EPS 10.30
P/E Ratio 16.08
Div & Yield 4.60 (2.80%)

Latest News

Closing Bell: PayPal Pushes Nasdaq to New Record; Crude Ends at One-Month Low

Closing Bell: PayPal Pushes Nasdaq to New Record; Crude Ends at One-Month Low

Better-than-expected earnings from PayPal drove the Nasdaq to new records, while a slump in crude oil kneecaps any big gains for the rest of the market.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

S&P 500, Dow Hold Slight Gains as Positive Earnings Counter Oil Slump

S&P 500, Dow Hold Slight Gains as Positive Earnings Counter Oil Slump

Stocks hold onto slight to modest gains Thursday afternoon after positive earnings help to offset a slump in crude oil prices and a decline in energy names.

Stocks Turn Mixed in Face of Crude Oil Slump

Stocks Turn Mixed in Face of Crude Oil Slump

Stocks turn mixed on Thursday after a slump in crude oil prices, and a decline in energy names, snarl earlier upward momentum.

Stock Futures Higher as Positive Earnings Offset Weaker Durable Goods Orders

Stock Futures Higher as Positive Earnings Offset Weaker Durable Goods Orders

Stock futures creep higher on Thursday as Wall Street returns its attention to positive earnings for market direction after a day focused on the White House's tax reform plans.

Amgen Reports Mixed Financials Results as Its Lead Drug, Enbrel, Sees Sales Decrease

Amgen Reports Mixed Financials Results as Its Lead Drug, Enbrel, Sees Sales Decrease

The drug company maintained its 2017 guidance, but sales of two of its key drugs registered disappointing results, and shares were down in after-hours trading 3%.

Market Recon: Today Is the Day You've Been Waiting For

Market Recon: Today Is the Day You've Been Waiting For

It is the day when the White House launches the start of President Trump's tax reform.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures are rising Wednesday as Wall Street awaits an announcement on tax cuts from the Trump administration.

Cramer: Nasdaq 6000 (the Number) vs. Nasdaq 2000 (the Year)

Cramer: Nasdaq 6000 (the Number) vs. Nasdaq 2000 (the Year)

You think the exchange is overvalued? I don't, and here's why.

Novartis, Amgen Divvy Global Marketing of New Migraine Drug

Novartis, Amgen Divvy Global Marketing of New Migraine Drug

Estimates for erenumab annual sales run as high as $2.3 billion.

Amgen Announces Expanded Commercial Collaboration With Novartis For Erenumab In Migraine

Amgen Announces Expanded Commercial Collaboration With Novartis For Erenumab In Migraine

Collaboration Designed to Maximize the Launch of First-in-Class Program and to More Effectively Reach People Living With Migraine

American Companies, Even Those Critical of Trump, Gave Big Bucks to Inauguration

American Companies, Even Those Critical of Trump, Gave Big Bucks to Inauguration

Corporate America shelled out big bucks for President Trump's inauguration.

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.

The Bulls Are Back in Town

The rally finally shows up, bringing much optimism.

Amgen Launches Neulasta® (pegfilgrastim) Onpro® NARRATIVES

Amgen Launches Neulasta® (pegfilgrastim) Onpro® NARRATIVES

Online News Resource Highlights Importance of Patient and Care Team Dialogue

Gilead, Pfizer, AbbVie Win From Lilly's Loss

Gilead, Pfizer, AbbVie Win From Lilly's Loss

The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.

Medivation Founder Takes Helm at Axovant, Shares Spike

Medivation Founder Takes Helm at Axovant, Shares Spike

David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.

Jim Cramer on What's Next for Amgen Shares

Jim Cramer on What's Next for Amgen Shares

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer sheds light on what's next for Amgen AMGN shares following its downgrade by Jefferies.

Amgen Receives Hold Rating at Jefferies -- Jim Cramer Says It Could Be a Battleground

Amgen Receives Hold Rating at Jefferies -- Jim Cramer Says It Could Be a Battleground

Jefferies lowered its rating on Amgen stock.

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.

As Biotech Roars Back, Amgen Remains Dirt Cheap

As Biotech Roars Back, Amgen Remains Dirt Cheap

The biotechnology sector is enjoying robust recovery, driving Big Pharma shares to lofty levels. But this biotech stalwart is a great value play now.

Amgen Submits Applications In The US And Europe To Expand Current Indication For XGEVA® (denosumab) To Include Patients With Multiple Myeloma

Amgen Submits Applications In The US And Europe To Expand Current Indication For XGEVA® (denosumab) To Include Patients With Multiple Myeloma

XGEVA is Currently Indicated for the Prevention of Skeletal-Related Events Known as Bone Complications in Patients With Solid Tumors

Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting

Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting

Preclinical Results for Mcl-1 Inhibitor for Multiple Myeloma Accepted as Oral Presentation